Hormone Therapy and Risk for Cancer in BRCA1 Mutation Carriers Hormone Therapy and Risk for Cancer in BRCA1 Mutation Carriers
Dr Andrew Kaunitz discusses the impact of hormone therapy on risk for breast cancer in BRCA carriers undergoing risk-reduction surgery.Medscape Ob/Gyn
This study is to compare breast cancer in elderly patients to their younger counterparts, and look for factors affecting survival of elderly patients.MethodologyA retrospective study of breast cancer patients who had surgery in a university hospital from 2000 to 2015 was performed. Stage on presentation, tumor characteristics and modalities of treatment for patients aged 70 and above were compared with those aged below 70. Factors affecting breast cancer specific survival were assessed by multivariate cox regression.Results3825 patients with breast cancer underwent surgery during the study period. 510 patients (13.3%) were...
Conclusions: This study describes a new approach to identify heterogenous effects when using an interrupted time series research design.
ConclusionsRadiotherapy plus hormonal therapy resulted in a significant improvement in the OS of elderly women diagnosed with HR+ BC.
ConclusionsThe combination of a homeopathic medicine and a hetero-isotherapic illustrates both the principles of “similarity” and “the identical”. It has proved to be an excellent response to the side effects of tamoxifen. By enhancing the patient’s quality of life, this combined approach also improved adherence to tr eatment.
New research shows that a lower dose of the hormone therapy Tamoxifen is as effective as the higher dose treatment in helping to prevent breast cancer from returning and guarding against new cancers in women who had high-risk breast tissue.
A targeted cancer drug added to hormone therapy has been shown to stunt cancer growth in women with newly diagnosed breast cancer.
(American Association for Cancer Research) Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according to data from the phase III STIC CTC clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. In the case of discrepancy between CTC count-based treatment choice and physician's choice of treatment, frontline chemotherapy was associated with a significant gain in overall survival.
Conclusion: Unlike the natural behavior of BD, which is well-defined to have an increased risk of thrombosis, BC patients with BD in this study did not have any adverse event. However, due to small sample size, it is difficult to drive any definite conclusion regarding the relation between these two pathologies.
ConclusionsCDK4/6 inhibition has become extremely prevalent in the recent times for hormone receptor positive breast cancer. We hypothesize that CDK4/6 inhibition produces reversible macrocytic anemia of unknown clinical significance. Given all patients had elevation in MCV along with complete radiologic remission, there is a possible causal relationship of elevated MCV and treatment response. The long-term clinical significance of observed macrocytosis and possible dysplasia, are important questions that need to be answered in large clinical trials.DisclosuresNo relevant conflicts of interest to declare.
No abstract available